NEFL and myeloid sarcoma: Baseline serum NfL levels were higher in MS patients as a whole (median NfL 10.06 ± IQR 7.61 pg/mL, n = 67) compared to controls (7.26 ± 4.62 pg/mL, Mann–Whitney p value = 0.004).